. Author manuscript; available in PMC: 2017 Nov 1.

Published in final edited form as: Urol Oncol. 2016 Sep 14;34(11):484.e19–484.e25. doi: 10.1016/j.urolonc.2016.05.033

Table 3. Multivariable Adjusted Comparison of BCG Connaught to BCG TICE: Patients without BCG maintenance.

		BCG Connaught (n=397) N, (%)	BCG Tice (n=937) N, (%)	Hazard Ratio (95% CI)	P value
Recurrence	No	199 (50.1)	381 (40.7)	1.48 (1.20 – 1.82)	< 0.001
Recurrence	Yes	198 (49.9)	556 (59.3)	1.48 (1.20 – 1.82)	< 0.001
Progression	No	313 (78.8)	764 (81.5)	1.21 (0.88 – 1.65)	0.24
Progression	Yes	84 (21.2)	173 (18.5)	1.21 (0.88 – 1.65)	0.24
Survival	Alive	290 (73.1)	701 (74.8)	1.18 (0.89 – 1.56)	0.25
Survival	Dead	107 (26.9)	236 (25.2)	1.18 (0.89 – 1.56)	0.25
Death Bladder Cancer	No	355 (89.4)	855 (91.2)	0.90 (0.57 – 1.40)	0.63
Death Bladder Cancer	Yes	42 (10.6)	82 (8.8)	0.90 (0.57 – 1.40)	0.63

HR > 1 favors Connaught, HR < 1 favors TICE